Mallinckrodt Presents Data on TERLIVAZ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) at the 2024 European Association for the Study of the Liver (EASL) Congress Jun 5, 2024 06:45AM
Mallinckrodt plc Reports First Quarter 2024 Financial Results and Reaffirms Full Year Guidance May 9, 2024 06:45AM
Mallinckrodt Announces Journal Publication of Real-World Data on Acthar® Gel (repository corticotropin injection) to Treat Symptomatic Sarcoidosis in African American and Non-African American Patient Mar 11, 2024 06:52AM
Mallinckrodt Completes Financial Restructuring and Irish Examinership Proceedings and Emerges From Chapter 11 Nov 14, 2023 06:05PM
Mallinckrodt plc Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides 2023 Guidance Feb 28, 2023 06:45AM


Nov 8, 2022 06:45AM Mallinckrodt plc Reports Third Quarter 2022 Financial Results and Reaffirms Guidance
Aug 17, 2022 06:46AM Mallinckrodt plc Provides Update on Executive Committee
Aug 11, 2022 06:00AM Mallinckrodt plc Reports Second Quarter 2022 Financial Results and Provides 2022 Financial Guidance